Neonatal death (death within the first 28 days of life) · women at risk of preterm birth
Strategies to increase use of antenatal corticosteroids probably leads to higher neonatal death before 28 days (at population level) compared with routine (usual) care (moderate certainty).
1 finding from 1 review
Stillbirth · women at risk of preterm birth
Strategies to increase use of antenatal corticosteroids probably leads to higher stillbirth (at population level) compared with routine (usual) care (moderate certainty).
1 finding from 1 review
Appropriate ACS treatment (women) · women at risk of preterm birth
Strategies to increase use of antenatal corticosteroids may leads to higher appropriate ACS treatment (women) compared with routine (usual) care (low certainty).
1 finding from 1 review
Inappropriate ACS treatment (women) · women at risk of preterm birth
Strategies to increase use of antenatal corticosteroids may leads to higher inappropriate ACS treatment (women) compared with routine (usual) care (low certainty).
1 finding from 1 review
Maternal infection or inflammation (at population level) · women at risk of preterm birth
Strategies to increase use of antenatal corticosteroids may leads to higher maternal infection or inflammation (at population level) compared with routine (usual) care (low certainty).
1 finding from 1 review
Maternal death · women at risk of preterm birth
Strategies to increase use of antenatal corticosteroids showed no clear difference in maternal mortality (at population level) compared with routine (usual) care (low certainty).
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.4 [1.23, 1.6]
41 studies · 41 participants
Very low
OR 1.7 [1.38, 2.09]
17 studies · 17 participants
Low
OR 1.22 [1.03, 1.45]
24 studies · 24 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Psychophysical testing for recovery of sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
It is very uncertain whether systemic corticosteroids plus intranasal… changes psychophysical testing for recovery of sense of smell compared with no intervention (very low certainty).
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3… showed no clear difference in mean number of oral ulcers compared with placebo (saline IM injection); GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review